Hitesh Kumar Maheshwari joins Ipca Labs as President - RnD (Formulations)
Mumbai: Ipca Labs has appointed Hitesh Kumar Maheshwari as President – R&D (Formulations) with effect from 16th October, 2023. "He will be responsible for leading all the activities related to the Research & Development (Formulations) Division of the Company," Ipca Labs informed in a BSE filing.Hitesh Maheshwari, aged 49 years has completed his B. Pharm from Devi Ahilya...
Mumbai: Ipca Labs has appointed Hitesh Kumar Maheshwari as President – R&D (Formulations) with effect from 16th October, 2023.
"He will be responsible for leading all the activities related to the Research & Development (Formulations) Division of the Company," Ipca Labs informed in a BSE filing.
Hitesh Maheshwari, aged 49 years has completed his B. Pharm from Devi Ahilya Vishwavidyalaya, Indore and M.Pharm from Panjab University, Chandigarh. Maheshwari brings with him a professional experience of over 24 years. He started his career with Ranbaxy Laboratories in the year 1999 and thereafter worked with Zydus Cadila Healthcare Ltd., Hikma Pharmaceuticals Ltd., Astron Research Ltd. and Macleods Pharmaceuticals Ltd.
Prior to joining Ipca, he was associated with Torrent Pharmaceuticals Ltd. as Executive Director and Head – R&D (Formulations).
Medical Dialogues team had earlier reported that the company's shareholders had approved the re-appointment of Pranay Godha as the Managing Director of the Company with effect from 11th November, 2023 for the period of five years till 10th November, 2028.
Read also: Ipca Labs shareholders approve re-appointment of Pranay Godha as MD
Ipca Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. The Company was founded by group of businessmen and medical professionals in 1949. It produces theobromine, acetyl thiophene, and p-bromotoluene as active pharmaceutical ingredients (APIs). Ipca sells these APIs and their intermediates globally. Ipca is a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments.
Read also: Ipca Labs buys 33.38 percent stake in Unichem for over Rs 945 crore
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd